What Researchers Did
This study reviewed the therapeutic potential of interleukin-10 (IL-10) in mitigating secondary damage and promoting recovery after spinal cord injury (SCI).
What They Found
Researchers found that interleukin-10 (IL-10) acts as an anti-inflammatory and anti-apoptotic cytokine, downregulating numerous pro-inflammatory and pro-apoptotic factors while upregulating anti-apoptotic factors. Immediate systemic administration of IL-10 post-spinal cord injury (SCI) led to increased tissue sparing, functional recovery, and neuroprotection, and it was successfully used in combination with other therapies.
What This Means for Canadian Patients
While still in research stages, the findings suggest that therapies targeting interleukin-10 (IL-10) could potentially reduce inflammation and cell death following spinal cord injury. This could lead to improved tissue preservation and functional recovery for Canadian patients suffering from this devastating condition.
Canadian Relevance
This study does not have a direct Canadian connection as it focuses on research conducted in the United States and does not involve Canadian researchers or institutions.
Study Limitations
The abstract indicates that chronic systemic administration of interleukin-10 may not be beneficial and could increase susceptibility to infections like septicemia and pneumonia.